Your SlideShare is downloading. ×
Recombinate Market [Hemophilia A and B] Forecast Trends Report
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Recombinate Market [Hemophilia A and B] Forecast Trends Report

53
views

Published on

Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022 …

Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.
Baxter’s Recombinate is a first-generation recombinant Factor VIII replacement therapy for hemophilia A patients. It is produced in CHO cells that express full-length recombinant FVIII. However, unlike Advate, Recombinate is produced in cells that are grown in the presence of human and animal serum as well as stabilized in human albumin.

Complete report available @ http://www.rnrmarketresearch.com/recombinate-hemophilia-a-and-b-forecast-and-market-analysis-to-2022-market-report.html

Scope
• Overview of Hemophilia A and B, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Recombinate including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Recombinate for the top nine countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China.
Request a Sample @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=145254
Reasons to buy
• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Recombinate performance
• Obtain sales forecast for Recombinate from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China)

Buy a copy of report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=145254

For further information on “Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022” report OR for any other business research / market intelligence need on the “Hematology Therapeutics” (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/hematology-therapeutics ), Contact sales@rnrmarketresearch.com / Call +1 888 391 5441.

Published in: Health & Medicine, Business

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
53
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022 by GlobalData Explore all reports for “ Hematology Therapeutics” market @ http://www.rnrmarketresearch.com/reports/lifesciences/pharmaceuticals/therapeutics/hematology-therapeutics . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  • 2. Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022 The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden. Baxter’s Recombinate is a first-generation recombinant Factor VIII replacement therapy for hemophilia A patients. It is produced in CHO cells that express fulllength recombinant FVIII. However, unlike Advate, Recombinate is produced in cells that are grown in the presence of human and animal serum as well as stabilized in human albumin. Request sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=145254 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  • 3. Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022 Scope • Overview of Hemophilia A and B, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. • Detailed information on Recombinate including product description, safety and efficacy profiles as well as a SWOT analysis. • Sales forecast for Recombinate for the top nine countries from 2012 to 2022. • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China. Complete report available @ http://www.rnrmarketresearch.com/recombinate-hemophilia-a-and-bforecast-and-market-analysis-to-2022-market-report.html © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  • 4. Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022 Reasons to buy • Understand and capitalize by identifying products that are most likely to ensure a robust return • Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential • Make more informed business decisions from insightful and in-depth analysis of Recombinate performance • Obtain sales forecast for Recombinate from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China) Request sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=145254 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  • 5. Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022 Table of Contents 1 Table of Contents 4 1.1 List of Tables 6 2 Introductions 7 2.1 Catalyst 7 2.2 Related Reports 8 2.3 Upcoming Related Reports 10 3 Disease Overview 11 3.1 Etiology and Path physiology 11 3.1.1 Etiology 11 3.1.2 Path physiology 12 Inquire For Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=145254 © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  • 6. Recombinate (Hemophilia A and B) – Forecast and Market Analysis to 2022 For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441 RnR Market Research RnRMarketResearch.com, an online repository of market research reports, offers in-depth analysis of over 5000 market segments. RnR Market Research library has syndicated reports by leading market research publishers across the globe. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441